Prevention and treatment of allergic asthma in pregnancy: from conventional drugs to new therapeutical approaches.
Standard
Prevention and treatment of allergic asthma in pregnancy: from conventional drugs to new therapeutical approaches. / Cadavid, Angela P; Bannenberg, Gérard L; Arck, Petra; Fitzgerald, Justine S; Markert, Udo R.
In: CURR PHARM BIOTECHNO, Vol. 12, No. 5, 5, 2011, p. 758-764.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prevention and treatment of allergic asthma in pregnancy: from conventional drugs to new therapeutical approaches.
AU - Cadavid, Angela P
AU - Bannenberg, Gérard L
AU - Arck, Petra
AU - Fitzgerald, Justine S
AU - Markert, Udo R
PY - 2011
Y1 - 2011
N2 - Different conventional anti-asthmatic and anti-allergic drugs are commonly used in pregnancy, including inhaled corticosteroids, long- and short-acting ?-agonists, leukotriene modifiers, cromolyn, and theophylline. Alternatively, immunotherapy with allergens before and during pregnancy is accepted as a causal treatment of allergies, but the allergy specifity and severity in combination with a variety of application protocols and procedures cause wide heterogenity of this treatment principle. Furthermore, the pharmacokinetic characteristics and the US Food and Drug Administration (FDA) classification of conventional anti-allergic drugs and immunological implications of immunotherapy are summarized in this review, and insights on fetal programming of allergies are introduced. We propose a potential perspective of treatment with anti-inflammatory and pro-resolving mediators, such as lipoxins, resolvins and protectins; these are lipid mediators physiologically generated during the immune response from arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid. This proposal fits with the recently appreciated approaches to allergy prevention for the newborn child by a balanced maternal nutrition and omega-3 long-chain polyunsaturated fatty acid consumption.
AB - Different conventional anti-asthmatic and anti-allergic drugs are commonly used in pregnancy, including inhaled corticosteroids, long- and short-acting ?-agonists, leukotriene modifiers, cromolyn, and theophylline. Alternatively, immunotherapy with allergens before and during pregnancy is accepted as a causal treatment of allergies, but the allergy specifity and severity in combination with a variety of application protocols and procedures cause wide heterogenity of this treatment principle. Furthermore, the pharmacokinetic characteristics and the US Food and Drug Administration (FDA) classification of conventional anti-allergic drugs and immunological implications of immunotherapy are summarized in this review, and insights on fetal programming of allergies are introduced. We propose a potential perspective of treatment with anti-inflammatory and pro-resolving mediators, such as lipoxins, resolvins and protectins; these are lipid mediators physiologically generated during the immune response from arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid. This proposal fits with the recently appreciated approaches to allergy prevention for the newborn child by a balanced maternal nutrition and omega-3 long-chain polyunsaturated fatty acid consumption.
KW - Animals
KW - Humans
KW - Female
KW - Pregnancy
KW - Anti-Allergic Agents/pharmacokinetics/therapeutic use
KW - Anti-Asthmatic Agents/pharmacokinetics/therapeutic use
KW - Asthma/drug therapy/immunology/prevention & control/therapy
KW - Desensitization, Immunologic/methods
KW - Hypersensitivity/drug therapy/immunology/prevention & control/therapy
KW - Pregnancy Complications/drug therapy/immunology/prevention & control/therapy
KW - Animals
KW - Humans
KW - Female
KW - Pregnancy
KW - Anti-Allergic Agents/pharmacokinetics/therapeutic use
KW - Anti-Asthmatic Agents/pharmacokinetics/therapeutic use
KW - Asthma/drug therapy/immunology/prevention & control/therapy
KW - Desensitization, Immunologic/methods
KW - Hypersensitivity/drug therapy/immunology/prevention & control/therapy
KW - Pregnancy Complications/drug therapy/immunology/prevention & control/therapy
U2 - 10.2174/138920111795470840
DO - 10.2174/138920111795470840
M3 - SCORING: Journal article
VL - 12
SP - 758
EP - 764
JO - CURR PHARM BIOTECHNO
JF - CURR PHARM BIOTECHNO
SN - 1389-2010
IS - 5
M1 - 5
ER -
